Bayer Stock News

FRANKFURT - Gute Nachrichten zum langwierigen US-Glyphosat-Rechtsstreit von Bayer DE000BAY0017 haben am Dienstagvormittag am Aktienmarkt für Begeisterung gesorgt.

(Kurse zum Handelsstart, neue Stimmen)FRANKFURT - Gute Nachrichten zum langwierigen US-Glyphosat-Rechtsstreit von Bayer DE000BAY0017 haben am Dienstagmorgen am Aktienmarkt für Begeisterung gesorgt.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide), Isovue® (iopami...

Die US-Investmentbank Goldman Sachs hat das Kursziel für Bayer DE000BAY0017 von 34,50 auf 38,50 Euro angehoben und die Einstufung auf "Buy" belassen.

Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical division that has struggled with setbacks and mounting litigation costs. The stock rose more than 9% and traded at €30.30—its highest level in over a week.

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.

Shares in Bayer jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that suffered a major development setback two years ago.

The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during the study.